Articles tagged with Vaccine Target
Researchers at Houston Methodist are working on a national consortium to develop vaccines against two common and destructive strains of herpesviruses. The project aims to create prophylactic and therapeutic vaccines using a computational toolkit that could transform vaccine development.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Researchers have conducted the largest genomic survey of the syphilis bacterium to date, correlating genetic data with clinical information to identify potential targets for a vaccine. The study found differences in bacterial strains between continents, but also similarities that suggest a global vaccine could be effective.
Researchers at La Jolla Institute for Immunology have captured the first detailed images of the Ebola virus nucleocapsid structure, which is crucial for replicating in host cells. This breakthrough may accelerate the development of universal antivirals that target this viral structure to combat multiple filoviruses.
A single dose of the Modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine was found to be 58% effective in preventing mpox infection in a recent study published in BMJ. The study used real-world health data to estimate the vaccine's effectiveness against mpox infection and included over 3,200 men who received the MVA-BN vaccine.
New vaccines are being explored as a promising approach to treating glioblastoma, a highly lethal brain cancer with limited treatment options. These vaccines have been generally well-tolerated and have shown promise in improving survival rates for GBM patients.
A new study published in Microorganisms highlights the importance of small molecule drugs that target the unchanging parts of the SARS-CoV-2 virus. The research suggests that these stable targets could provide a consistent and reliable treatment option for COVID-19, even as vaccines are updated to address changing viral strains.
Researchers in China used a scenario experiment to test messaging strategies on COVID-19 vaccine uptake. The study found that emphasizing personal risk rather than personal gain or community benefits was most effective in persuading people to get vaccinated.
Researchers have developed a highly sensitive mass spectrometry-based method to detect mutation-derived tumor neoepitopes, which are recognized by the immune system. The new protocol enables the detection of low-abundance peptides in minimal tissue samples, paving the way for personalized cancer immunotherapies.
Scientists discovered that T follicular helper cells indirectly control the anti-influenza response, leading to less effective immunity. The study found that the current flu vaccine formulation could be improved by excluding internal proteins and targeting surface proteins.
A recent study has confirmed the efficacy and safety of the dengue vaccine TAK-003, which reduces the risk of contracting the disease by over 50%. The vaccine has shown a high safety profile, with more than 90% of adults and children developing antibodies after administration.
Scientists used AI to identify genes that can convert brain cancer cells into immune cells, increasing survival chances by up to 75% in mouse models. The approach bypasses the blood-brain barrier, offering new hope for aggressive cancers.
A Cleveland Clinic-led study found that maternal Zika virus infections can reprogram fetal immune development, leading to long-term consequences in children's immunity. The changes occur even in children born without physical or neurological symptoms of congenital Zika syndrome, suggesting a broader impact.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Researchers at Trinity College Dublin have made a breakthrough in understanding how to improve vaccine responses against the potentially deadly MRSA bacterium. By targeting the immune-suppressive molecule IL-10, they improved the ability of vaccines to protect against infection and reduce bacterial clearance.
A study published in JAMA Network Open found no association between RSV vaccination during late pregnancy and increased risk of preterm birth or poor outcomes. The research provides real-world evidence supporting the safety of Pfizer's Abrysvo vaccine, offering reassurance to patients and clinicians.
Researchers analyzed genomic data and human travel patterns to understand the spread and evolution of Streptococcus pneumoniae. The study found that a pneumococcal vaccine reduced antibiotic resistance but allowed non-targeted strains to gain a competitive advantage, suggesting short-lived protection.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
A multinational research team has identified a novel way to attack measles by targeting specific proteins on the virus, paving the way for new vaccines and antiviral drugs. The study found that antibodies against the fusion protein successfully prevented the virus from completing its merger with the cell membrane.
AlphaFold's groundbreaking ability to predict protein structures is set to transform predictive medicine, enabling the development of personalized vaccines and adaptive clinical trials. However, the review also highlights crucial challenges and ethical considerations surrounding AI integration with clinical data.
Human papillomavirus (HPV) is a major cause of several cancers, with cervical cancer being the most prominent. Persistent infection with high-risk HPV types can lead to malignant transformation. Vaccination and screening programs are crucial in preventing HPV-related cancers.
Researchers at La Jolla Institute for Immunology found that people who experienced breakthrough COVID-19 infections develop T cells better equipped to recognize and target SARS-CoV-2. The study also discovered that B cells produce more diverse antibodies targeting common epitopes between the vaccine and variants.
The 2022-2023 mpox outbreak in the Netherlands declined due to infection-induced immunity in high-risk groups, highlighting the importance of prompt vaccination implementation and ongoing surveillance. The study recommends swift vaccination programs and continuous monitoring to mitigate future outbreaks.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have found a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas. Adding an immune-boosting agent, poly-ICLC, to a personalized dendritic cell vaccine improves the immune response and activity of T cells in patients.
Researchers have identified new cellular targets for a vaccine to treat eczema in children, which may limit the severity of symptoms and reduce antibiotic use. The study uncovered specific immune signatures in children with infected flares of eczema, providing a potential blueprint for future therapies.
A late University of Virginia School of Medicine scientist's research on the SAS1B protein could lead to new cancer treatments for multiple cancers. The discovery has the potential to selectively target cancer cells while sparing healthy tissue.
A team of scientists has developed a novel vaccine approach that induces long-lasting protective immunity against SARS-CoV-2 virus in pre-clinical models. The Clec9A-RBD antibody construct targets specific dendritic cells, leading to exceptional durability of immune responses and potential to address shortcoming of current mRNA vaccines.
Researchers developed a new 'proactive vaccinology' approach to build vaccines before disease-causing pathogens emerge. The Quartet Nanocage vaccine trains the immune system to target specific regions of eight coronaviruses, providing broad protection against known and unknown strains.
A new study reveals that chronic hepatitis B is globally undertreated, especially among women and Asian minorities in the West. The research highlights the need for targeted outreach to reduce new infections and deaths, with oral antiviral therapy being a lifesaving but underutilized treatment option.
Researchers at Duke University have developed a new vaccine strategy that targets the portion of the flu virus surface with less variability, aiming for universal and long-lasting protection. The experimental vaccine elicits an immune response focused on the stalk region, which remains consistent despite viral mutations.
A new survey of 23,000 respondents from 23 countries reports mixed signals on the current acceptance of vaccines generally, especially COVID-19 boosters. The study found that global uptake of at least one COVID-19 vaccine dose rose to 87.8%, but intent to get a booster was lower compared to previous years.
The global cervical cancer vaccine roll-out has shown significant effectiveness in reducing HPV-related diseases. However, there are huge variations in coverage between countries, with high-income nations leading the way and many low- and middle-income countries lagging behind. Globally, only 44% of girls have received at least one dos...
A rapidly spreading virus is attacking cacao trees in Ghana, resulting in harvest losses of between 15-50%. Researchers have developed a new strategy to combat the spread of the disease using mathematical data to determine safe planting distances for vaccinated trees.
Researchers at UC Riverside demonstrate a new vaccine strategy targeting a common viral genome part, eliminating the need for annual booster shots. The vaccine uses small RNA molecules to boost the immune system, making it safe for babies and those with weakened immunity.
Researchers at Butantan Institute used phage display to screen 12,000 proteins from Schistosoma mansoni, identifying key parasite peptides targeted by macaque antibodies. This approach has potential for developing candidate vaccines against the disease.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
A study found that an annual vaccination campaign with a second dose for children under 2 years old and individuals aged 50 and over can significantly reduce hospitalizations, deaths, and healthcare spending. The optimal timing for the second vaccination is delivering it 5 months after initial vaccination.
A department-wide EHR optimization project led to improved productivity by addressing workflow problems and creating new policies. The study demonstrates the importance of ongoing collaboration between EHR users and IT colleagues to enhance user experience and inform technology upgrades.
A recent study found that digital reminders for flu vaccination increased vaccination rates among older adults in Denmark by one percentage point. However, it did not improve clinical outcomes, including hospitalization and death rates.
A recent study published in Lancet Infectious Diseases found that vaccinated individuals had a lower risk of severe COVID-19 outcomes compared to unvaccinated individuals. The study also showed significant reductions in hospitalization and death rates from COVID-19, particularly among older individuals and those with compromised immune...
A novel antibody constant region variant (REW) extends plasma half-life and improves biodistribution, allowing for both invasive and non-invasive delivery. The REW technology also enhances the complement system, providing enhanced ability to kill cancer cells and bacteria.
A Zika vaccine candidate has been shown to be safe and effective when administered both before and during pregnancy, according to a new study. The purified, inactivated vaccine (ZPIV) candidate prevented placental damage and blocked transmission of Zika virus from mother to fetus.
A study by Texas A&M University found that only 9% of older Americans had been vaccinated against RSV prior to this fall and winter. The study also revealed that men were more likely to be vaccinated than women, and those who were vaccinated had higher levels of concern about the disease.
A new study from Uppsala University found that people who have had herpes virus are twice as likely to develop dementia as those who have never been infected. The researchers studied 1,000 70-year-olds over 15 years and confirmed previous research on the potential link between herpes and dementia.
An experimental mRNA vaccine against CMV elicited promising immune responses, outperforming a previous vaccine candidate in preventing the virus from infecting epithelial cells. The new vaccine may protect adults against CMV, potentially preventing women from passing the infection to their babies during pregnancy.
Researchers at La Jolla Institute for Immunology have identified 137 unique T cell epitopes targeted by the immune system in patients with active TB. These findings may lead to the development of new diagnostics and therapies for the disease, which affects over 1.3 million people worldwide.
Researchers created a DNA-based vaccine that mimics the structure of a virus, inducing a strong antibody response against SARS-CoV-2. The vaccine uses a DNA scaffold carrying viral proteins, allowing the immune system to focus on the target antigen.
La Jolla Institute researchers discovered that prior exposure to a common cold coronavirus partially protects mice from lung damage during a subsequent SARS-CoV-2 infection. Harnessing 'cross-reactive' T cells may lead to novel vaccines with broad, pan-coronavirus protection.
A new study published in Nature Communications has provided structural insights into a potent antimalarial drug candidate's interaction with the malaria parasite Plasmodium falciparum. The research suggests that the drug, TDI-8304, can selectively target and kill resistant parasites, offering hope for more effective treatments against ...
A team of researchers from UMass Amherst and Seattle Children's Research Institute found that prior exposure to certain bacteria changes the lung's innate immune response, making it more vulnerable to tuberculosis. The study suggests that remodeling the innate immune system could be a more effective strategy in fighting TB.
Three different HIV antibodies independently protected monkeys from acquiring SHIV, providing statistically significant protection and dose-dependent effect. The findings support the HIV fusion peptide as a promising preventive vaccine target.
Researchers at UC San Diego School of Medicine found that the immune system's response to Staphylococcus aureus bacteria can be tricked into producing non-protective antibodies, making vaccines ineffective. The study suggests targeting subdominant antigens for future vaccine development.
The 2024 adult immunization schedule features four new vaccines, including the respiratory syncytial virus (RSV) vaccine, mpox vaccine, a new MenACWY-MenB combo vaccine, and updated versions of the COVID-19 vaccine. Clinicians stress the need for effective communication strategies to increase vaccine uptake among skeptical patients.
A Phase I trial demonstrated that a vaccine targeting KRAS mutations delayed relapse in patients with high-risk pancreatic and colorectal cancer. The vaccine induced significant T cell responses, which correlated with reduced risk of relapse.
Mayo Clinic researchers used genetic sequencing to study the measles virus's spread in a human brain. The study found that the virus acquired distinct mutations that drove its spread from the frontal cortex outward. This knowledge may help develop effective antiviral drugs to combat SSPE, a rare and lethal brain disease caused by measles.
A study by researchers at the Medical University of Vienna found that natural killer cells may play a crucial role in protecting against multiple sclerosis (MS) disease. The investigation revealed that strong EBV-specific and autoreactive immune responses combined with poor autoimmunity control increase MS risk.
Scientists have developed a new system to display epitopes in mammal cells for immunization studies, potentially speeding up the immunization process. This method allows for targeted immune responses against specific viral proteins without the need to purify antigens.
Researchers at La Jolla Institute for Immunology found that most T cells can still target epitopes on the new Pirola variant, suggesting people may be able to mount a response against it. The study's findings provide positive news in the fight against SARS-CoV-2, emphasizing the importance of vaccination with updated vaccines.
Researchers at Scripps Research have designed a novel flu vaccine that utilizes nanoparticles to present the M2e protein fragment, which is relatively conserved across different influenza A strains. The vaccine showed promising results in initial animal tests, providing strong protection against both seasonal and pandemic strains.
Researchers have developed a needle-free ultrasound vaccine delivery technique that produces a higher immune response than traditional methods. By harnessing acoustic energy to clear passages and drive drug molecules into cells, the approach shows promise in reducing costs and increasing efficacy while minimizing risks.